The Zhitong Finance App learned that according to the Hong Kong Stock Exchange's disclosure on October 25, Sichuan Xinhehua Chinese Medicine Co., Ltd. (Xinhehua) passed the Hong Kong Stock Exchange's main board listing hearing, and GF Securities and Agricultural Bank International were co-sponsors. According to the prospectus, New Lotus is a major supplier of traditional Chinese medicine (“TCM”) tablet products (i) in China. According to Frost & Sullivan's data, based on revenue from Chinese herbal medicine products in 2025, New Lotus ranked 2nd in China, accounting for 0.4% of the market share in a highly competitive market pattern, while the top five market participants together held 2.7% of the market share.

Zhitongcaijing · 6d ago
The Zhitong Finance App learned that according to the Hong Kong Stock Exchange's disclosure on October 25, Sichuan Xinhehua Chinese Medicine Co., Ltd. (Xinhehua) passed the Hong Kong Stock Exchange's main board listing hearing, and GF Securities and Agricultural Bank International were co-sponsors. According to the prospectus, New Lotus is a major supplier of traditional Chinese medicine (“TCM”) tablet products (i) in China. According to Frost & Sullivan's data, based on revenue from Chinese herbal medicine products in 2025, New Lotus ranked 2nd in China, accounting for 0.4% of the market share in a highly competitive market pattern, while the top five market participants together held 2.7% of the market share.